You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 272 No. 21, December 7, 1994 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorials
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

A Randomized Controlled Trial of Influenza Vaccine in the Elderly

Scientific Scrutiny and Ethical Responsibility

Peter A. Patriarca, MD

JAMA. 1994;272(21):1700-1701.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Influenza viruses have arguably caused more morbidity and mortality than any infectious agent in recorded history. Seven pandemics of influenza have occurred during the past century alone, one of which—the infamous Spanish (swine) flu—was responsible for at least 20 million deaths worldwide. Of even greater concern has been the occurrence of annual epidemics of varying severity that have resulted in more than 599 000 excess deaths in the United States during the past 40 years.1-3 Although complacency regarding influenza is widely prevalent owing to the misperception that it is simply a mild respiratory or gastrointestinal infection,2 one needs only to briefly examine accounts of recent outbreaks to appreciate the explosive potential for influenza viruses to cause life-threatening illness.4 The unusual properties of the virus' genome, including a high frequency of point mutations (which cause the hemagglutinin [HA] and neuraminidase [NA] molecules to drift

See also p 1661. . . . [Full Text PDF of this Article]


Author Affiliations

From the Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Md.


Footnotes

Corresponding author: Peter A. Patriarca, MD, Food and Drug Administration, HFM-30, 1401 Rockville Pike, Rockville, MD 20852.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.